BionFarming
BionFarming GmbH is a Berlin-area biotechnology company that develops phototrophic expression platforms using cyanobacteria and plant systems for sustainable production of recombinant proteins, peptides and biologics. The organisation focuses on closed, modular cultivation systems, glycosylation engineering, downstream processing and protein analytics to enable scalable, lower-cost manufacturing for pharmaceutical, industrial and environmental applications.
Industries
Nr. of Employees
small (1-50)
BionFarming
Neuendorfstraße 18a, 16761 Hennigsdorf, Germany
Products
Alpha‑1‑antitrypsin (AAT) — plant-derived candidate
Plant-derived alpha‑1‑antitrypsin in development as a lower-cost alternative to existing production methods.
Plant-derived trastuzumab biosimilar (vegan trastuzumab)
Development of a plant-based biosimilar of trastuzumab intended as an animal-free alternative for antibody therapy.
Fibroblast growth factor 2 (FGF2)
Phototrophically produced FGF2 targeting tissue regeneration and wound-healing applications.
Interferon alpha 2
Cyanobacterial expression of interferon alpha 2 with correct disulfide bonds for antiviral and immune-modulatory uses.
LL-37 and defensins (antimicrobial peptides)
Production of human and defensin-class antimicrobial peptides for therapeutic and hygiene applications.
Other biologics in development (antibodies, biobetters, fusion proteins, virus-like particles)
Pipeline focus on a range of difficult-to-synthesise proteins and biologics produced in plant or cyanobacterial hosts.
Alpha‑1‑antitrypsin (AAT) — plant-derived candidate
Plant-derived alpha‑1‑antitrypsin in development as a lower-cost alternative to existing production methods.
Plant-derived trastuzumab biosimilar (vegan trastuzumab)
Development of a plant-based biosimilar of trastuzumab intended as an animal-free alternative for antibody therapy.
Fibroblast growth factor 2 (FGF2)
Phototrophically produced FGF2 targeting tissue regeneration and wound-healing applications.
Interferon alpha 2
Cyanobacterial expression of interferon alpha 2 with correct disulfide bonds for antiviral and immune-modulatory uses.
LL-37 and defensins (antimicrobial peptides)
Production of human and defensin-class antimicrobial peptides for therapeutic and hygiene applications.
Other biologics in development (antibodies, biobetters, fusion proteins, virus-like particles)
Pipeline focus on a range of difficult-to-synthesise proteins and biologics produced in plant or cyanobacterial hosts.
Services
Development and scale-up of expression workflows in cyanobacterial and plant hosts for therapeutic proteins, enzymes and peptides.
Development and scale-up of expression workflows in cyanobacterial and plant hosts for therapeutic proteins, enzymes and peptides.
Expertise Areas
- Plant molecular farming
- Cyanobacterial biomanufacturing
- Protein expression and folding for disulfide-rich proteins
- Glycosylation engineering
Key Technologies
- Cyanobacterial phototrophic cultivation
- Closed modular bioreactors (CyanoSphere-style)
- Carbon-concentrating mechanisms (CCM)
- Nutrient reservoir cultivation systems (NRT)
News & Updates
Relocation and expansion to a new site in Hennigsdorf with more than 500 m² additional laboratory and production area to increase capacity.
Release of a podcast episode discussing cyanobacteria and the platform technology with co-founders and staff.
Article describing platform use to produce antimicrobial peptides at scale, including reported efficacy against multidrug-resistant strains and mention of GMP compliance for clinical applications.
Announcement of development of a plant clonal expression system intended to create reproducible expression chassis for pharmaceutical and biotech use.
Report on expanded analytical capabilities and laboratory infrastructure for protein quality and quantity analysis (BSL-1).
Report on collaboration with an academic chair to provide analytical support and scientific rigour for platform development.
Relocation and expansion to a new site in Hennigsdorf with more than 500 m² additional laboratory and production area to increase capacity.
Release of a podcast episode discussing cyanobacteria and the platform technology with co-founders and staff.
Article describing platform use to produce antimicrobial peptides at scale, including reported efficacy against multidrug-resistant strains and mention of GMP compliance for clinical applications.
Announcement of development of a plant clonal expression system intended to create reproducible expression chassis for pharmaceutical and biotech use.
Report on expanded analytical capabilities and laboratory infrastructure for protein quality and quantity analysis (BSL-1).
Report on collaboration with an academic chair to provide analytical support and scientific rigour for platform development.